BayMark Announces the Acquisition of Its First U.S.-Based Residential Treatment Facility

Liberty Bay in Portland, Maine joins Greenestone in Bala, Ontario as BayMark expands their addiction treatment portfolio into the Residential Treatment Services market.

BayMark Health Services announced this week an exciting addition to their portfolio of Substance Use Disorder Services, Liberty Bay Recovery Center, a residential treatment facility in Portland, Maine. BayMark is well-known in the addiction treatment industry as the North American leader in Opioid Use Disorder treatment with more than 250 facilities across the continent providing a variety of treatment options including medication-assisted treatment, counseling and both inpatient and outpatient withdrawal management services.

That portfolio, until recently, included only one residential treatment facility in Bala, Ontario, Greenestone Muskoka. The addition of Liberty Bay is a gratifying one for the company whose mission to improve the lives of individuals with substance use disorders will be well-served by bringing both their clinical and administrative expertise into a new U.S. treatment space.

David K. White, Ph.D, Chief Executive Office of BayMark Health Services shares, “The field of addiction treatment offers more options to patients than at any time in history and we’re proud to be a part of innovating the treatment itself, as well as improving access to all those in need. Each patient is unique, and as BayMark expands our continuum of care, what we’re really expanding is our ability to help each of those patients find the type and level of care that is right for them on their path to recovery.”

Liberty Bay offers treatment for a variety of addictions including not only opioids, but also alcohol, cocaine, methamphetamine, prescription drugs and other substances. Multiple levels of care including residential, partial hospitalization and intensive outpatient treatment provide patients with step-down care that meets each patient where they are at in their journey. Patients at Liberty Bay receive a customized treatment plan that may include both group and individual counseling, family program work, addiction education, life skills classes, relapse prevention strategies and resources, and around-the-clock supervision and support.

“Providing the ability of a patient anywhere in this country to access professional, comprehensive and compassionate care for addiction is our number one goal”, shared Mike Saul, BayMark Division President. “As we move into the residential space I couldn’t be more pleased to be working with Liberty Bay. Their facility, staff and the care provided is top-notch, and the foundation of excellence in patient care is one that BayMark will work diligently to not only maintain, but enhance.”

In addition to Liberty Bay, BayMark operates two medication-assisted treatment facilities in Portland and Lewiston, ME offering methadone and Suboxone^®, as well as counseling, for the treatment of Opioid Use Disorder.

Mertz Taggart, a leading mergers and acquisitions firm, represented Liberty Bay in this transaction.

For more information about Liberty Bay, visit: www.LibertyBayRecovery.com.

About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to 53,000+ patients in recovery from substance use disorder across the United States and Canada. Our outpatient programs deliver medically-supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances.

The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.